116 related articles for article (PubMed ID: 29803730)
21. Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer.
Njar VC; Brodie AM
Curr Pharm Des; 1999 Mar; 5(3):163-80. PubMed ID: 10066888
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development.
Baston E; Leroux FR
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):31-58. PubMed ID: 18221052
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
Owen CP; Dhanani S; Patel CH; Shahid I; Ahmed S
Bioorg Med Chem Lett; 2006 Aug; 16(15):4011-5. PubMed ID: 16750362
[TBL] [Abstract][Full Text] [Related]
24. YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells.
Ideyama Y; Kudoh M; Tanimoto K; Susaki Y; Nanya T; Nakahara T; Ishikawa H; Fujikura T; Akaza H; Shikama H
Jpn J Pharmacol; 1999 Feb; 79(2):213-20. PubMed ID: 10202857
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase.
Stefanachi A; Favia AD; Nicolotti O; Leonetti F; Pisani L; Catto M; Zimmer C; Hartmann RW; Carotti A
J Med Chem; 2011 Mar; 54(6):1613-25. PubMed ID: 21341743
[TBL] [Abstract][Full Text] [Related]
26. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
Gianti E; Zauhar RJ
J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
[TBL] [Abstract][Full Text] [Related]
27. New biaryl-chalcone derivatives of pregnenolone via Suzuki-Miyaura cross-coupling reaction. Synthesis, CYP17 hydroxylase inhibition activity, QSAR, and molecular docking study.
Al-Masoudi NA; Kadhim RA; Abdul-Rida NA; Saeed BA; Engel M
Steroids; 2015 Sep; 101():43-50. PubMed ID: 26051784
[TBL] [Abstract][Full Text] [Related]
28. Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
Clement OO; Freeman CM; Hartmann RW; Handratta VD; Vasaitis TS; Brodie AM; Njar VC
J Med Chem; 2003 Jun; 46(12):2345-51. PubMed ID: 12773039
[TBL] [Abstract][Full Text] [Related]
29. A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21.
Drăgan CA; Hartmann RW; Bureik M
J Enzyme Inhib Med Chem; 2006 Oct; 21(5):547-56. PubMed ID: 17194026
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of the P450 enzymes aromatase and lyase. Crystallographic and molecular modeling studies suggest structural features of pyridylacetic acid derivatives responsible for differences in enzyme inhibitory activity.
Laughton CA; Neidle S
J Med Chem; 1990 Nov; 33(11):3055-60. PubMed ID: 2231605
[TBL] [Abstract][Full Text] [Related]
31. At the crossroads of steroid hormone biosynthesis: the role, substrate specificity and evolutionary development of CYP17.
Gilep AA; Sushko TA; Usanov SA
Biochim Biophys Acta; 2011 Jan; 1814(1):200-9. PubMed ID: 20619364
[TBL] [Abstract][Full Text] [Related]
32. Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors.
Gumede NJ; Nxumalo W; Bisetty K; Escuder Gilabert L; Medina-Hernandez MJ; Sagrado S
Bioorg Chem; 2020 Jan; 94():103462. PubMed ID: 31818479
[TBL] [Abstract][Full Text] [Related]
33. A novel molecular modelling study of inhibitors of the 17alpha-hydroxylase component of the enzyme system 17alpha-hydroxylase/17,20-lyase (P-450(17alpha)).
Ahmed S
Bioorg Med Chem; 1999 Aug; 7(8):1487-96. PubMed ID: 10482440
[TBL] [Abstract][Full Text] [Related]
34. Novel mutation of the CYP17 gene in two unrelated patients with combined 17alpha-hydroxylase/17,20-lyase deficiency: demonstration of absent enzyme activity by expressing the mutant CYP17 gene and by three-dimensional modeling.
Patocs A; Liko I; Varga I; Gergics P; Boros A; Futo L; Kun I; Bertalan R; Toth S; Pazmany T; Toth M; Szücs N; Horanyi J; Glaz E; Racz K
J Steroid Biochem Mol Biol; 2005 Nov; 97(3):257-65. PubMed ID: 16176874
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biochemical evaluation of a range of sulfonated derivatives of 4-hydroxybenzyl imidazole as highly potent inhibitors of rat testicular 17alpha-hydroxylase/17,20-lyase (P-450(17alpha)).
Ahmed S; Shahid I; Dhanani S; Owen CP
Bioorg Med Chem Lett; 2009 Aug; 19(16):4698-701. PubMed ID: 19608417
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
Hu Q; Negri M; Jahn-Hoffmann K; Zhuang Y; Olgen S; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
Bioorg Med Chem; 2008 Aug; 16(16):7715-27. PubMed ID: 18674917
[TBL] [Abstract][Full Text] [Related]
37. 17alpha-hydroxylase/17,20-lyase deficiency caused by a novel homozygous mutation (Y27Stop) in the cytochrome CYP17 gene.
Müssig K; Kaltenbach S; Machicao F; Maser-Gluth C; Hartmann MF; Wudy SA; Schnauder G; Häring HU; Seif FJ; Gallwitz B
J Clin Endocrinol Metab; 2005 Jul; 90(7):4362-5. PubMed ID: 15811924
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of 17alpha-hydroxylase/C17,20-lyase (CYP17) from rat testis by green tea catechins and black tea theaflavins.
Kimura K; Itakura Y; Goto R; Tojima M; Egawa N; Yoshihama M
Biosci Biotechnol Biochem; 2007 Sep; 71(9):2325-8. PubMed ID: 17827674
[TBL] [Abstract][Full Text] [Related]
39. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis.
Rowlands MG; Barrie SE; Chan F; Houghton J; Jarman M; McCague R; Potter GA
J Med Chem; 1995 Oct; 38(21):4191-7. PubMed ID: 7473546
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Pinto-Bazurco Mendieta MA; Negri M; Jagusch C; Müller-Vieira U; Lauterbach T; Hartmann RW
J Med Chem; 2008 Aug; 51(16):5009-18. PubMed ID: 18672868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
